glp-1 liver disease Multiple target tissue effects of analogues on non-alcoholic fatty (NAFLD) and non-alcoholic steatohepatitis (NASH) Frontiers | Future Perspectives on
Description
Cocaine, methamphetamine, nicotine, alcohol, opioids, converging on a shared mesolimbic mechanism
Clean formulas aligned with GLP-1 nutrition needs
Discover its potential benefits
Why you'll like it T
Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity
